IOL Chemicals & Pharmaceuticals Ltd

BSE: IOLCP524164ISIN INE485C01029

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹183.55+8.85 (+5.07%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

Splits and bonuses

11 Mar 2025 · Split 5:1 (₹10 → ₹2)

52W high: ₹224.00
52W low: ₹67.14
Off 52W high: -18.06%
1M return: -10.72%
3M return: +12.23%
6M return: +91.30%
1Y return: +97.64%
20D avg volume: 1,87,649
50 DMA: ₹193.67
200 DMA: ₹130.56

Key ratios Consolidated

Market cap: ₹5,388 Cr
Current price: ₹183.55
52W high / low: ₹224.00 / ₹67.14
Face value: ₹2.00
P/E: 26.51
P/B: 2.80
EPS (TTM): ₹6.92
Book value / share: ₹65.60
ROE: —
ROCE: 10.50%
Operating margin: —
Net margin: —
Debt / equity: 0.07
Net debt: ₹66.65 Cr
Interest cover: 13.67
Dividend yield: 0.54%
Dividend / share (TTM): ₹1.00
Payout: 14.45%
Cash conversion cycle: 77.3 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	795.03	756.26	619.45	580.39	567.53	551.69	527.78	523.30	525.75	502.38	503.92	520.39
	5.51	8.18	1.84	5.29	6.88	7.37	4.53	4.07	6.43	7.38	7.52	8.38
	800.54	764.44	621.29	585.68	574.41	559.06	532.31	527.37	532.18	509.76	511.44	528.77
	713.25	677.75	550.48	546.92	533.92	513.55	487.61	499.57	506.24	470.24	474.24	496.68
	505.31	506.76	401.66	356.70	366.70	376.55	347.61	335.96	351.75	323.02	349.30	358.06
	0.00	0.75	3.83	0.19	0.00	0.00	0.00	—	—	—	—	—
	68.71	71.21	70.33	56.93	63.35	57.65	52.39	52.43	58.70	53.05	49.65	48.29
	5.44	3.64	3.21	3.63	3.48	4.23	4.03	4.46	4.12	2.15	3.41	4.30
	22.20	21.34	20.29	20.18	19.99	19.77	18.55	18.68	17.94	16.82	16.43	16.34
	115.58	103.58	84.39	83.74	78.93	67.67	66.85	69.95	69.84	61.85	82.23	71.80
	87.29	86.69	70.81	38.76	40.49	45.51	44.70	27.80	25.94	39.52	37.20	32.09
	0.00	0.00	0.00	-11.21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	87.29	86.69	70.81	27.55	40.49	45.51	44.70	27.80	25.94	39.52	37.20	32.09
	22.22	22.29	17.65	6.97	10.52	11.58	13.28	7.27	6.79	9.55	9.58	9.01
	65.07	64.40	53.16	20.58	29.97	33.93	31.42	20.53	19.15	29.97	27.62	23.08
	2.21	2.20	1.81	0.70	1.02	1.16	1.07	3.50	3.26	5.11	4.71	3.93
Key metrics
	114.93	111.67	94.31	51.36	63.96	69.51	67.28	50.94	48.00	58.49	57.04	52.73
	14.50%	14.80%	15.20%	8.80%	11.30%	12.60%	12.70%	9.70%	9.10%	11.60%	11.30%	10.10%
	8.20%	8.50%	8.60%	3.50%	5.30%	6.20%	6.00%	3.90%	3.60%	6.00%	5.50%	4.40%
	4.60%	—	3.90%	—	2.40%	—	2.70%	—	—	—	—	—
	40.10%	37.10%	17.40%	10.90%	7.90%	9.80%	4.70%	0.60%	—	—	—	—
	117.10%	89.80%	69.20%	0.20%	56.50%	13.20%	13.80%	-11.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	2,751	2,319	2,079	2,133	2,217	2,184
	20.82	21.38	22.41	30.07	25.61	32.04
	2,772	2,340	2,102	2,163	2,243	2,216
	2,488	2,145	1,964	1,981	2,054	1,977
	1,770	1,502	1,358	1,435	1,536	1,579
	4.77	4.02	0.00	0.15	29.22	43.90
	267.18	248.26	216.57	201.02	168.21	141.30
	15.92	14.55	14.76	16.10	16.47	8.29
	84.01	80.23	71.99	62.91	46.16	43.26
	387.29	314.73	268.49	304.23	276.14	213.92
	283.55	195.57	137.96	181.65	188.65	238.78
	-11.21	-11.21	0.00	0.00	0.00	-13.93
	272.34	184.36	137.96	181.65	188.65	224.85
	69.13	46.72	36.89	47.22	49.51	57.18
	203.21	137.64	101.07	134.43	139.14	167.67
	6.92	4.69	3.44	22.90	23.70	28.56
Key metrics
	372.27	279.14	224.71	260.66	251.28	276.40
	13.53%	12.00%	10.80%	12.20%	11.30%	12.70%
	7.39%	5.90%	4.90%	6.30%	6.30%	7.70%
	—	10.50%	8.60%	—	—	—
	26.76%	11.50%	-2.50%	-3.80%	1.50%	—
	75.41%	36.20%	-24.80%	-3.40%	-17.00%	—
	—	41.33	-34.93	—	—	—
	—	1.56	1.77	—	—	—
	—	0.07	0.07	—	—	—
	—	66.65	38.87	—	—	—
	—	77.3	78.4	—	—	—
Balance sheet
	—	2,587	2,382	—	—	—
	—	1,228	1,151	—	—	—
	—	65.35	78.17	—	—	—
	—	603.13	513.69	—	—	—
	—	371.07	360.62	—	—	—
	—	44.11	59.61	—	—	—
	—	1,165	1,158	—	—	—
	—	482.56	427.56	—	—	—
	—	690.18	609.91	—	—	—
	—	132.00	117.04	—	—	—
	—	132.00	117.04	—	—	—
	—	0.00	0.00	—	—	—
	—	1,799	1,688	—	—	—
Cash flow
	—	214.32	178.62	—	—	—
	—	-198.11	-154.18	—	—	—
	—	-29.03	46.04	—	—	—
	—	172.99	213.55	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	795.03	756.26	619.45	580.39	567.53	551.69	527.78	523.30	525.75	502.38	503.92	520.39
	5.51	8.18	1.74	5.29	6.88	7.37	4.52	4.07	6.43	7.38	7.52	8.38
	800.54	764.44	621.19	585.68	574.41	559.06	532.30	527.37	532.18	509.76	511.44	528.77
	713.29	677.67	550.36	546.92	533.89	513.52	487.40	499.55	506.24	470.53	473.67	496.53
	505.31	506.76	401.66	356.70	366.70	376.55	347.61	335.96	351.75	323.02	349.30	358.06
	0.00	0.75	3.83	0.19	0.00	0.00	0.00	—	—	—	—	—
	68.71	71.21	70.33	56.93	63.35	57.65	52.39	52.43	58.70	53.05	49.65	48.29
	5.44	3.64	3.21	3.63	3.48	4.23	4.03	4.46	4.12	2.15	3.41	4.30
	22.19	21.32	20.27	20.17	19.98	19.75	18.53	18.66	17.93	16.80	16.42	16.32
	115.63	103.52	84.29	83.75	78.91	67.66	66.66	69.95	69.85	62.16	81.67	71.67
	87.25	86.77	70.83	38.76	40.52	45.54	44.90	27.82	25.94	39.23	37.77	32.24
	0.00	0.00	0.00	-11.21	0.00	0.00	0.00	—	—	—	—	—
	87.25	86.77	70.83	27.55	40.52	45.54	44.90	27.82	25.94	39.23	37.77	32.24
	22.22	22.29	17.65	6.97	10.52	11.58	13.28	7.27	6.79	9.55	9.58	9.01
	65.03	64.48	53.18	20.58	30.00	33.96	31.62	20.55	19.15	29.68	28.19	23.23
	2.21	2.20	1.81	0.70	1.02	1.16	1.08	3.50	3.26	5.06	4.80	3.96
Key metrics
	114.88	111.73	94.31	51.35	63.98	69.52	67.46	50.94	47.99	58.18	57.60	52.86
	14.40%	14.80%	15.20%	8.80%	11.30%	12.60%	12.80%	9.70%	9.10%	11.60%	11.40%	10.20%
	8.20%	8.50%	8.60%	3.50%	5.30%	6.20%	6.00%	3.90%	3.60%	5.90%	5.60%	4.50%
	4.60%	—	3.90%	—	2.40%	—	2.80%	—	—	—	—	—
	40.10%	37.10%	17.40%	10.90%	7.90%	9.80%	4.70%	0.60%	—	—	—	—
	116.80%	89.90%	68.20%	0.10%	56.70%	14.40%	12.20%	-11.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	2,751	2,319	2,079	2,133	2,217	2,184
	20.72	21.28	22.40	30.07	25.57	32.04
	2,772	2,340	2,102	2,163	2,243	2,216
	2,488	2,145	1,964	1,980	2,053	1,979
	1,770	1,502	1,358	1,435	1,536	1,579
	4.77	4.02	0.00	0.15	29.22	43.90
	267.18	248.26	216.57	201.02	168.21	141.30
	15.92	14.55	14.76	16.10	16.47	8.29
	83.95	80.17	71.92	62.85	46.13	43.26
	387.19	314.61	268.62	303.30	275.29	215.93
	283.61	195.65	137.89	182.64	189.49	236.77
	-11.21	-11.21	0.00	—	—	-13.93
	272.40	184.44	137.89	182.64	189.49	222.84
	69.13	46.72	36.89	47.22	49.51	57.18
	203.27	137.72	101.00	135.42	139.98	165.66
	6.92	4.69	3.44	23.07	23.84	28.22
Key metrics
	372.27	279.16	224.57	261.59	252.09	274.39
	13.53%	12.00%	10.80%	12.30%	11.40%	12.60%
	7.39%	5.90%	4.90%	6.30%	6.30%	7.60%
	—	10.50%	8.60%	—	—	—
	26.76%	11.50%	-2.50%	-3.80%	1.50%	—
	75.04%	36.40%	-25.40%	-3.30%	-15.50%	—
	—	41.43	-34.87	—	—	—
	—	1.56	1.77	—	—	—
	—	0.07	0.07	—	—	—
	—	66.71	39.02	—	—	—
	—	77.3	78.4	—	—	—
Balance sheet
	—	2,587	2,382	—	—	—
	—	1,228	1,151	—	—	—
	—	65.29	78.02	—	—	—
	—	603.13	513.69	—	—	—
	—	371.07	360.62	—	—	—
	—	44.10	59.60	—	—	—
	—	1,165	1,158	—	—	—
	—	482.56	427.56	—	—	—
	—	690.12	609.87	—	—	—
	—	132.00	117.04	—	—	—
	—	132.00	117.04	—	—	—
	—	0.00	0.00	—	—	—
	—	1,798	1,687	—	—	—
Cash flow
	—	214.42	178.68	—	—	—
	—	-198.12	-154.23	—	—	—
	—	-29.03	46.04	—	—	—
	—	172.99	213.55	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +1.51%
Sales CAGR 5Y: —
Profit CAGR 3Y: -0.54%
Profit CAGR 5Y: —
Sales YoY (TTM): +26.76%
Profit YoY (TTM): +75.04%

Consolidated

Sales CAGR 3Y: +1.51%
Sales CAGR 5Y: —
Profit CAGR 3Y: -0.36%
Profit CAGR 5Y: —
Sales YoY (TTM): +26.76%
Profit YoY (TTM): +75.41%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 62.29%

Holder	Type	Holding	Previous	Change
NM MERCHANTILES LIMITED	Promoter Group	21.88%	—	—
MAYA DEVI POLYCOT LIMITED	Promoter Group	21.79%	—	—
NCVI ENTERPRISES LIMITED	Promoter Group	16.58%	—	—
VARINDER GUPTA	Promoter	2.04%	—	—
POLUNIN EMERGING MARKETS SMALL CAP FUND, LLC	Public	1.51%	—	—
VARINDER GUPTA (HUF)	Promoter Group	0.00%	—	—
DIMPLE GUPTA	Promoter Group	0.00%	—	—
ABHIRAJ GUPTA	Promoter Group	0.00%	—	—
VIKAS GUPTA (HUF)	Promoter Group	0.00%	—	—
VIKAS GUPTA	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
IOL Chemicals & Pharmaceuticals Ltd	5,388	183.55	26.51	10.50%	+26.76% TTM	+75.41% TTM	+97.64%

Filings & corporate actions

Recent announcements

Audio Recording of Earnings Call on the Q2 & H1 FY 27 Financial Results2 Nov 2026 · Company Update / Analyst / Investor Meet
Investor Presentation- Q2 & H1 FY272 Nov 2026 · Company Update / Investor Presentation
Submission of newspaper publication of un-audited Financial Results for the quarter and half year ended 30th September 20262 Nov 2026 · Company Update / Newspaper Publication
Press Release30 Oct 2026 · Company Update / Press Release / Media Release
Outcome of the Board Meeting and submission of Unaudited Financial Results of the Company for the quarter and half year ended 30th September 202630 Oct 2026 · Board Meeting / Outcome of Board Meeting
Submission of Financial Results30 Oct 2026 · Result / Financial Results
Schedule of analyst / investor conference call - Q2 & H1 FY2728 Oct 2026 · Company Update / Analyst / Investor Meet
IOL Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve the Un-audited ....23 Oct 2026 · Board Meeting / Board Meeting
Newspaper Publication17 Oct 2026 · Company Update / Newspaper Publication
Certificate under Regulation 75(5) of SEBI (DP) Regulations7 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
CEP for Fenofibrate - Process II25 Sep 2026 · Company Update / General
Intimation of Closure of Trading Window25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
EU-REACH Registration for Triacetin23 Sep 2026 · Company Update / General
Schedule of Analyst/Institutional Investor Meeting23 Sep 2026 · Company Update / Analyst / Investor Meet
Schedule of Analyst/Institutional Investor Meeting23 Sep 2026 · Company Update / Analyst / Investor Meet
Dispatch of Reminder letter to Shareholders to Update KYC21 Sep 2026 · Company Update / General
Transcript of Business Update Call with Investors and Analysts17 Sep 2026 · Company Update / Analyst / Investor Meet
Audio Recording of Business Update Call with Investors and Analysts11 Sep 2026 · Company Update / Analyst / Investor Meet
Business Update Conference Call to discuss the Company's recent business developments and strategic growth initiatives with investors and analysts10 Sep 2026 · Company Update / Analyst / Investor Meet
Expansion of Ibuprofen Capacity, New CDMO Business for Pharmaceutical Formulation and Dedicated Specialty Chemicals Manufacturing Facility9 Sep 2026 · Company Update / General
Voting Results and Scrutinizer''s Report2 Sep 2026 · AGM/EGM / AGM
Outcome of the AGM2 Sep 2026 · AGM/EGM / AGM
Schedule of Analyst/Institutional Investor Meeting26 Aug 2026 · Company Update / Analyst / Investor Meet
Earning Call Transcript20 Aug 2026 · Company Update / Earnings Call Transcript
Submission of Newspaper Publication18 Aug 2026 · Company Update / Newspaper Publication
Audio Recording of Analysts/Investors Call pertaining to the Financial Results Q1- FY202713 Aug 2026 · Company Update / Analyst / Investor Meet
Investor Presentation12 Aug 2026 · Company Update / Investor Presentation
Communication to the Shareholders regarding AGM Notice ansd Annual Report for the Financial Year 2025-2611 Aug 2026 · Company Update / General
Submission of newspaper publication of unaudited Financial Results for the quarter ended 30th June 202611 Aug 2026 · Company Update / Newspaper Publication
Press Release- Financial Results for the quarter ended 30th June 202610 Aug 2026 · Company Update / Press Release / Media Release
Submission of Unaudited Financial Results of the Company for the quarter ended 30th June 202610 Aug 2026 · Result / Financial Results
Outcome of the Board Meeting and submission of Unaudited Financial Results of the Company for the quarter ended 30th June 202610 Aug 2026 · Board Meeting / Outcome of Board Meeting
Copy of notice published in Newspapers8 Aug 2026 · Company Update / Newspaper Publication
Schedule of analyst / investor conference call - Q1 FY277 Aug 2026 · Company Update / Analyst / Investor Meet
Submission of BRSR FY 2025-267 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Notice of 39th Annual General Meeting7 Aug 2026 · AGM/EGM / AGM
Submission of Integrated Annual Report for FY 2025-267 Aug 2026 · Others / Reg. 34 (1) Annual Report
IOL Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve the Un-audited ....3 Aug 2026 · Board Meeting / Board Meeting
Newspaper Publication3 Aug 2026 · Company Update / Newspaper Publication
Approval from NMPA,China foe Clopidogrel Bisulfate API14 Jul 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Interim Dividend - Rs. - 1.0000	17 Feb 2026	17 Feb 2026	—
Stock Split From Rs.10/- to Rs.2/-	11 Mar 2025	11 Mar 2025	—
Interim Dividend - Rs. - 4.0000	18 Feb 2025	18 Feb 2025	—

Board meetings

30 Oct 2026 Board Meeting - Financial Results
10 Aug 2026 Board Meeting - Financial Results